Moreover, despite an initial benefit of the targeted drug in molecularly well-defined tumors, patients inevitably experience tumor progression due to the development of resistance (i.e., Crizotinib in ALK-rearranged NSCLC population and CNS relapses) [967]. The gene discussed is ALK; the disease is neoplasm.